Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved..
Selpercatinib and pralsetinib are potent and selective tyrosine kinase inhibitors targeting the rearranged during transfection (RET) receptor in various types of cancer. In this study, a bioanalytical assay was developed and fully validated for selpercatinib and pralsetinib in mouse plasma and partially in eight mouse tissue homogenates using liquid chromatograph-tandem mass spectrometry. Samples were pre-treated by protein precipitation with acetonitrile using erlotinib as internal standard. Separation of the analytes was performed on an ethylene bridged octadecyl silica C18 column by gradient elution using ammonium hydroxide (in water) and methanol. Analytes were detected by positive electrospray ionization in selected reaction monitoring mode. A linear concentration range of 2-2000 ng/ml was used for the validation of the assay for both inhibitors. The precision values (within-day and between-day) ranged between 3.4 and 10.2% for selpercatinib and 3.1-14.6% for pralsetinib in all matrices. Furthermore, data obtained for accuracy were between 91.7 and 109.3% and 85.1-114.1% for selpercatinib and pralsetinib, respectively. No significant matrix effects or extraction losses were observed and both analytes were stable under all investigated conditions. Finally, a pilot study for selpercatinib in mice was conducted employing this method, followed by a successful incurred sample reanalysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1147 |
|---|---|
| Enthalten in: |
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences - 1147(2020) vom: 15. Juni, Seite 122131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Şentürk, Rahime [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CEGM9YBNGD |
|---|
| Anmerkungen: |
Date Completed 26.02.2021 Date Revised 26.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jchromb.2020.122131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309992443 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309992443 | ||
| 003 | DE-627 | ||
| 005 | 20231225135127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jchromb.2020.122131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM309992443 | ||
| 035 | |a (NLM)32416592 | ||
| 035 | |a (PII)S1570-0232(20)30358-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Şentürk, Rahime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2021 | ||
| 500 | |a Date Revised 26.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Selpercatinib and pralsetinib are potent and selective tyrosine kinase inhibitors targeting the rearranged during transfection (RET) receptor in various types of cancer. In this study, a bioanalytical assay was developed and fully validated for selpercatinib and pralsetinib in mouse plasma and partially in eight mouse tissue homogenates using liquid chromatograph-tandem mass spectrometry. Samples were pre-treated by protein precipitation with acetonitrile using erlotinib as internal standard. Separation of the analytes was performed on an ethylene bridged octadecyl silica C18 column by gradient elution using ammonium hydroxide (in water) and methanol. Analytes were detected by positive electrospray ionization in selected reaction monitoring mode. A linear concentration range of 2-2000 ng/ml was used for the validation of the assay for both inhibitors. The precision values (within-day and between-day) ranged between 3.4 and 10.2% for selpercatinib and 3.1-14.6% for pralsetinib in all matrices. Furthermore, data obtained for accuracy were between 91.7 and 109.3% and 85.1-114.1% for selpercatinib and pralsetinib, respectively. No significant matrix effects or extraction losses were observed and both analytes were stable under all investigated conditions. Finally, a pilot study for selpercatinib in mice was conducted employing this method, followed by a successful incurred sample reanalysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LC-MS/MS | |
| 650 | 4 | |a Mouse plasma | |
| 650 | 4 | |a Pralsetinib | |
| 650 | 4 | |a RET inhibitor | |
| 650 | 4 | |a Selpercatinib | |
| 650 | 4 | |a Tissue homogenate | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a pralsetinib |2 NLM | |
| 650 | 7 | |a selpercatinib |2 NLM | |
| 650 | 7 | |a CEGM9YBNGD |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Ret protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Wang, Yaogeng |e verfasserin |4 aut | |
| 700 | 1 | |a Schinkel, Alfred H |e verfasserin |4 aut | |
| 700 | 1 | |a Beijnen, Jos H |e verfasserin |4 aut | |
| 700 | 1 | |a Sparidans, Rolf W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of chromatography. B, Analytical technologies in the biomedical and life sciences |d 2002 |g 1147(2020) vom: 15. Juni, Seite 122131 |w (DE-627)NLM117075906 |x 1873-376X |7 nnns |
| 773 | 1 | 8 | |g volume:1147 |g year:2020 |g day:15 |g month:06 |g pages:122131 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jchromb.2020.122131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1147 |j 2020 |b 15 |c 06 |h 122131 | ||